Company Profile
Aziyo Biologics Stock Price, News & Catalysts
- Ticker:
- AZYO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
The latest monitored company update is “Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch.” The corresponding closing-price reaction is not yet available.
Company overview
Drug-Eluting Biomatrix Company
Elutia, formerly known as Aziyo Biologics, develops biologic matrices designed to support tissue repair while delivering antimicrobial protection at the surgical site.
Antibiotic-Eluting Platform
The company's biomatrix technology incorporates antibiotics into a biologic scaffold. The platform was first applied around implantable cardiac devices and is now being extended into plastic and reconstructive surgery.
NXT-41
NXT-41 is a biologic matrix intended for soft-tissue reinforcement in plastic and reconstructive procedures. It serves as the non-antibiotic foundation for the broader product family.
NXT-41x
NXT-41x adds local antibiotic elution to the biomatrix, with the goal of reducing infection risk in reconstructive surgery while preserving tissue integration.
Future catalysts
- FDA clearance decision for NXT-41 in the fourth quarter of 2026.
- FDA clearance decision for NXT-41x in the first half of 2027.
- Commercial soft launch of NXT-41x in the second half of 2027.
- Full commercial launch of NXT-41x in 2028.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Aziyo Biologics do?
Drug-Eluting Biomatrix Company Elutia, formerly known as Aziyo Biologics, develops biologic matrices designed to support tissue repair while delivering antimicrobial protection at the surgical site. Antibiotic-Eluting Platform The company's biomatrix technology incorporates antibiotics into a biologic scaffold. The platform was first applied around...
On which exchange is AZYO stock listed?
Aziyo Biologics (AZYO) is associated with NASDAQ, United States, Biopharma.
What is NXT-41?
FDA clearance decision for NXT-41 in the fourth quarter of 2026.
Which conditions is Aziyo Biologics targeting with NXT-41?
FDA clearance decision for NXT-41 in the fourth quarter of 2026.
How does Aziyo Biologics describe recent progress with NXT-41?
FDA clearance decision for NXT-41 in the fourth quarter of 2026.
What is Drug-Eluting?
Drug-Eluting Biomatrix Company Elutia, formerly known as Aziyo Biologics, develops biologic matrices designed to support tissue repair while delivering antimicrobial protection at the surgical site.
What should investors watch for with Drug-Eluting?
FDA clearance decision for NXT-41 in the fourth quarter of 2026. FDA clearance decision for NXT-41x in the first half of 2027. Commercial soft launch of NXT-41x in the second half of 2027. Full commercial launch of NXT-41x in 2028.
What is Biomatrix?
Drug-Eluting Biomatrix Company Elutia, formerly known as Aziyo Biologics, develops biologic matrices designed to support tissue repair while delivering antimicrobial protection at the surgical site.